Vascular PAR-1: activity and antagonism

Lang, N. N. , Guðmundsdóttir, I. J. and Newby, D. E. (2011) Vascular PAR-1: activity and antagonism. Cardiovascular Therapeutics, 29(6), pp. 349-361. (doi: 10.1111/j.1755-5922.2010.00140.x) (PMID:20528879)

Full text not currently available from Enlighten.


Despite major advances in antiplatelet therapies, recurrent cardiovascular events remain high after acute coronary syndrome. Furthermore, incremental benefits achieved in the reduction of atherothrombotic events have almost always been at the expense of hemorrhagic side effects. Thrombin is the most potent platelet activating factor known and it makes important interactions with the endothelium and vascular smooth muscle with proinflammatory, proatherogenic effects. Distinct from its activity within the coagulation cascade, thrombin mediates these effects via protease‐activated receptor type 1 (PAR‐1) in man. This review discusses the role of PAR‐1 in the vasculature and the development of novel PAR‐1 antagonists. These drugs may provide important antiatherothrombotic effects without attendant bleeding complications and could represent a major breakthrough for the treatment of cardiovascular diseases.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Newby, Professor David and Lang, Dr Ninian
Authors: Lang, N. N., Guðmundsdóttir, I. J., and Newby, D. E.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Cardiovascular Therapeutics
ISSN (Online):1755-5922
Published Online:25 November 2011

University Staff: Request a correction | Enlighten Editors: Update this record